Patents by Inventor Marshall Porter

Marshall Porter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250034637
    Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.
    Type: Application
    Filed: August 8, 2024
    Publication date: January 30, 2025
    Applicant: Roche Sequencing Solutions, Inc.
    Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
  • Patent number: 12091714
    Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.
    Type: Grant
    Filed: February 21, 2023
    Date of Patent: September 17, 2024
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
  • Publication number: 20230332222
    Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.
    Type: Application
    Filed: February 21, 2023
    Publication date: October 19, 2023
    Applicant: Roche Sequencing Solutions, Inc.
    Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
  • Patent number: 11613778
    Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: March 28, 2023
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
  • Patent number: 11150233
    Abstract: Described herein are nanopore protein conjugates that can be used in DNA sequencing reactions. The nanopore protein conjugates includes a nanopore protein monomer that is joined to a DNA binding domain. The nanopore protein monomer is available to oligomerize with other nanopore protein monomers, while the DNA binding domain is available to bind to a template DNA strand. In certain examples, the nanopore protein monomer is an alpha-hemolysin monomer or variant thereof and the DNA binding domain is an Sso7d protein or variant thereof, such as an Sso7d-like protein. Also provided are nanopore protein assemblies incorporating the nanopore protein conjugates, along with methods of using the nanopore protein assemblies in sequencing reactions.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: October 19, 2021
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Timothy Craig, Corissa Harris, Matt Dipetro, Mark Ambroso, Yaozhong Zou, Marshall Porter, Issa Delkaninia, Alexxa Noble, James Fairman, Wiseley Wu, Kapil Bajaj, Giovanni Bellesia, Seong-Ho Shin
  • Publication number: 20210230683
    Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L1351 in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.
    Type: Application
    Filed: January 25, 2021
    Publication date: July 29, 2021
    Applicant: Roche Sequencing Solutions, Inc.
    Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
  • Patent number: 10934582
    Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L1351 in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: March 2, 2021
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
  • Publication number: 20200216887
    Abstract: A method is provided for preparing nanopore sequencing complexes in membranes for sequencing of polymers, e.g., polynucleotides and polypeptides. The nanopore sequencing complex is formed by the sequential linking of an enzyme to a nanopore that is inserted in a membrane, and of a polymer to the enzyme. Alternatively, the nanopore sequencing complex is formed by linking a preformed enzyme-polymer complex to a nanopore that is inserted in a membrane. The enzyme polymer complex is interchangeable.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 9, 2020
    Applicant: Genia Technologies, Inc.
    Inventors: Timothy Kellogg Craig, Christos Tzitzilonis, Alexander H. Yang, Liv E. Jensen, Marshall Porter, Charlotte Yang, Corissa Harris, Matt Dipetro
  • Publication number: 20190376134
    Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L1351 in the mature alpha-hemolysin amino acid sequence. The a-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.
    Type: Application
    Filed: July 23, 2019
    Publication date: December 12, 2019
    Applicant: Roche Sequencing Solutions, Inc.
    Inventors: Mark Ambroso, Timothy Craig, Matthew DePietro, Corissa Harris, Marshall Porter
  • Publication number: 20190079067
    Abstract: Described herein are nanopore protein conjugates that can be used in DNA sequencing reactions. The nanopore protein conjugates includes a nanopore protein monomer that is joined to a DNA binding domain. The nanopore protein monomer is available to oligomerize with other nanopore protein monomers, while the DNA binding domain is available to bind to a template DNA strand. In certain examples, the nanopore protein monomer is an alpha-hemolysin monomer or variant thereof and the DNA binding domain is an Sso7d protein or variant thereof, such as an Sso7d-like protein. Also provided are nanopore protein assemblies incorporating the nanopore protein conjugates, along with methods of using the nanopore protein assemblies in sequencing reactions.
    Type: Application
    Filed: September 28, 2018
    Publication date: March 14, 2019
    Applicant: GENIA TECHNOLOGIES, INC.
    Inventors: Timothy Craig, Corissa Harris, Matt Dipetro, Mark Ambroso, Yaozhong Zou, Marshall Porter, Issa Delkaninia, Alexxa Noble, James Fairman, Wiseley Wu, Kapil Bajaj, Giovanni Bellesia, Seong-Ho Shin
  • Publication number: 20180002750
    Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.
    Type: Application
    Filed: June 29, 2017
    Publication date: January 4, 2018
    Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
  • Publication number: 20060051569
    Abstract: A vehicle bumper (20) integrates rigid and flexible components into a single co-injection molded structure. In a preferred embodiment, a flexible fascia (58) is provided with integrated rigid fastener brackets (62, 66, 70, 71), energy absorption structure and head lamp brackets and housings (62). A method for manufacturing such a bumper provides for the injection of two different plastic materials during the same molding process. The flexible plastic material first injected into the mold. Then, the rigid plastic material is injected at gates located where the rigid material is desired. In one embodiment, the rigid material is completely contained within the flexible material. The rigid material may be either a higher stiffness plastic or a fiber reinforced plastic.
    Type: Application
    Filed: October 31, 2005
    Publication date: March 9, 2006
    Inventors: Marshall Porter, Norman Guschewski, Michael Smith, Keith Korte, Todd Parker, Russell York